A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

May 22, 2023 updated by: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS

This trial is an open-lable , multi-center, Phase 1/Phase 2 study that will evaluate the safety, tolerability, Pharmacokinetics, Pharmacodynamics and and immunogenicity of IMM01 combined with Azacitidine in patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Main study purpose:

  • To evaluate the safety and tolerability of IMM01 combined with Azacitidine in patients with AML and MDS.
  • To explore the Maximum Tolerated Dose (MTD) of IMM01 combined with Azacitidine, and determine the phase 2 clinical recommended dose (RP2D) of IMM01 combined with Azacitidine.

Secondary study purpose:

  • To evaluate the efficacy of IMM01 combined with Azacitidine in patients with AML and MDS.
  • To evaluate the Pharmacokinetics and Pharmacodynamics of IMM01 combined with Azacitidine, in patients with AML and MDS.

Exploratory study purpose:

• To evaluate the immunogenicity of IMM01 combined with Azacitidine in patients with AML and MDS.

Study Type

Interventional

Enrollment (Anticipated)

126

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
      • Beijing, China
      • Beijing, China
        • Recruiting
        • Xuanwu Hospital, Capital Medical University
        • Contact:
      • Beijing, China
      • Chongqing, China
      • Chongqing, China
      • Fuzhou, China
      • Ganzhou, China
      • Guangzhou, China
      • Guangzhou, China
      • Guangzhou, China
        • Recruiting
        • Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Southern Medical University
        • Contact:
      • Hangzhou, China
        • Recruiting
        • The First Affiliated Hospital Zhejiang University School of Medicine
        • Contact:
      • Nanchang, China
      • Shanghai, China
        • Recruiting
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        • Contact:
      • Shanghai, China
        • Recruiting
        • Tongren Hospital Shanghai Jiaotong University School of Medicine
        • Contact:
      • Shanghai, China
      • Shenyang, China
      • Shenyang, China
        • Recruiting
        • Shengjing Hospital affiliated to China Medical University
        • Contact:
      • Tianjin, China
      • Wuhan, China
        • Recruiting
        • Union Hospital Tongji Medical College Huazhong University Of Science And Technology
        • Contact:
      • Xuzhou, China
      • Zhengzhou, China
      • Zhengzhou, China

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Voluntary participation and written informed consent.
  2. Males and females ≥18 years of age
  3. The Eastern Oncology Collaboration (ECOG) Status of ≤2
  4. Life expectancy of at least 3 months.
  5. Women and men of reproductive age must agree and use effective contraception during the study period and for three months after the last administration of IMM01, and women of reproductive age must have negative pregnancy test results within seven days prior to administration.
  6. White blood cell count ≤ 20×10⁹/L before the first treatment of the study drug (treatment with hydroxyurea is permitted, but not within 3 days before the first treatment of the study drug).
  7. Bone marrow aspiration and bone marrow biopsy were agreed during screening and treatment.
  8. For those who have received previous chemotherapy or targeted drug therapy, the interval between the first drug administration should be more than 2 weeks;Prior treatment with chimeric antigen receptor T cells (CAR T cells) should be discontinued for at least 12 weeks after initial dosing(for Cohort 1 and 2).
  9. Non-hematological adverse reactions have been restored to grade 1 and below (NCI-CTC AE v5.0, except residual hair loss effect),in patients with previous chemotherapy and targeted drug therapy. Hematologic adverse reactions recovered to investigatory-determined acceptance of study drug administration (for cohort 1 and 2).
  10. Appropriate organ functions.

Exclusion Criteria:

  1. Received anti-CD47 antibody or SIRPα fusion protein research drugs.
  2. Who has received allogeneic hematopoietic stem cell transplantation and other organ transplants; Autologous hematopoietic stem cell transplantation less than six months.
  3. Central nervous system leukemia orcentral nervous system invasion.

  4. Developed other malignant tumors within 5 years prior to enrollment.Except:

    Cured carcinoma in situ and non-melanoma skin cancer of the cervix; Complete remission of disease at least 2 years prior to initial administration and no need for antineoplastic therapy.

  5. Patients with a history of active autoimmune diseases;
  6. Major surgery within 4 weeks prior to initial treatment;
  7. Subjects requiring systemic corticosteroids (equivalent to >10 mg prednisone/day) or other immunosuppressive agents within 14 days prior to initial treatment or during the study period;
  8. Hypertension (systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg) or pulmonary hypertension or unstable angina that is also not controlled by medication;
  9. Patients with a history of arterial or deep vein thrombosis within the 6 months prior to enrollment, or evidence or history of bleeding tendency within the 2 months prior to enrollment, regardless of severity.
  10. Severe gastrointestinal diseases;
  11. With acute lung disease, pulmonary fibrosis, Severe dyspnea, lung insufficiency or continuous oxygen inhalation.
  12. Patients who have been severely infected within 4 weeks prior to initial administration;
  13. Active hepatitis B or hepatitis C ; human immunodeficiency virus (HIV) antibody is positive.
  14. Live attenuated vaccine should be administered within 4 weeks prior to initial administration.
  15. Patients with a history of severe allergy to protein drugs (CTCAE V5.0 grade > 3); Or the patient is allergic to azacytidine.
  16. Participate in clinical trials of other drugs 28 days prior to initial dosing.
  17. A history of prior neurological or mental disorders, such as epilepsy, dementia, or alcohol, drug or substance abuse, affects compliance.
  18. Other conditions that the investigator considers inappropriate for participation in this clinical trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Relapse/Refractory AML

IMM01 and Azacitidine in Relapse/Refractory AML

Interventions:

Drug: IMM01 Drug: Azacitidine
Drug: IMM01
IMM01 is intravenously once a week, every 28 days for a treatment cycle;
Other Names:
  • IMM01 Ingection
Drug: Azacitidine
Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
Other Names:
  • Vidaza
Experimental: Relapsed or Refractory MDS

IMM01 and Azacitidine in Relapse/Refractory MDS

Interventions:

Drug: IMM01 Drug: Azacitidine
Drug: IMM01
IMM01 is intravenously once a week, every 28 days for a treatment cycle;
Other Names:
  • IMM01 Ingection
Drug: Azacitidine
Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
Other Names:
  • Vidaza
Experimental: Treatment naive AML

IMM01 and Azacitidine in treatment naive AML

Interventions:

Drug: IMM01 Drug: Azacitidine
Drug: IMM01
IMM01 is intravenously once a week, every 28 days for a treatment cycle;
Other Names:
  • IMM01 Ingection
Drug: Azacitidine
Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
Other Names:
  • Vidaza
Experimental: Treatment naive MDS and naive CMML

IMM01 and Azacitidine in treatment naive MDS and naive CMML

Interventions:

Drug: IMM01 Drug: Azacitidine
Drug: IMM01
IMM01 is intravenously once a week, every 28 days for a treatment cycle;
Other Names:
  • IMM01 Ingection
Drug: Azacitidine
Azacitidine 75 mg/m/ day is administered subcutaneously for 7 consecutive days, with each 28-day treatment cycle planned for 6 treatment cycles
Other Names:
  • Vidaza

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence rate and the grade (severity) of dose-limiting toxicities (DLTs) of IMM01 combination azacitidine
Time Frame: Though end of DLT evaluation period,up to approximately 28 days.
To be summarized using descriptive statistics
Though end of DLT evaluation period,up to approximately 28 days.
Maximum Tolerated Dose (MTD)
Time Frame: Dose-limiting toxicities will be evaluated during the first cycle (28 days) of treatment.
MTD is the highest dose in patients with DLT incidence <1/3.For a dose group to be assessed as MTD, at least 6 DLT data must be available to evaluate the subject.
Dose-limiting toxicities will be evaluated during the first cycle (28 days) of treatment.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pharmacokinetics - Cmax
Time Frame: Within 60 minutes prior to infusion on Cycle 1 Day 1, Day 8, Day 15 and Cycle 2-6 Day 1 (28 days cycle).10 minutes post-infusion on Cycle 1 Day 15 and Cycle 6 Day 22 (28 days cycle ) .10 minutes and 4 hours post-infusion on Cycle 1 Day 1 (28 days cycle).
Maximum observed concentration in serum
Within 60 minutes prior to infusion on Cycle 1 Day 1, Day 8, Day 15 and Cycle 2-6 Day 1 (28 days cycle).10 minutes post-infusion on Cycle 1 Day 15 and Cycle 6 Day 22 (28 days cycle ) .10 minutes and 4 hours post-infusion on Cycle 1 Day 1 (28 days cycle).
Pharmacokinetics - AUC
Time Frame: Within 60 minutes prior to infusion on Cycle 1 Day 1, Day 8, Day 15 and Cycle 2-6 Day 1 (28 days cycle).10 minutes post-infusion on Cycle 1 Day 15 and Cycle 6 Day 22 (28 days cycle ) .10 minutes and 4 hours post-infusion on Cycle 1 Day 1 (28 days cycle).
Area under the serum concentration - time curve
Within 60 minutes prior to infusion on Cycle 1 Day 1, Day 8, Day 15 and Cycle 2-6 Day 1 (28 days cycle).10 minutes post-infusion on Cycle 1 Day 15 and Cycle 6 Day 22 (28 days cycle ) .10 minutes and 4 hours post-infusion on Cycle 1 Day 1 (28 days cycle).
Pharmacokinetics - tmax
Time Frame: Within 60 minutes prior to infusion on Cycle 1 Day 1, Day 8, Day 15 and Cycle 2-6 Day 1 (28 days cycle).10 minutes post-infusion on Cycle 1 Day 15 and Cycle 6 Day 22 (28 days cycle ) .10 minutes and 4 hours post-infusion on Cycle 1 Day 1 (28 days cycle).
Time to peak (maximum) serum concentration
Within 60 minutes prior to infusion on Cycle 1 Day 1, Day 8, Day 15 and Cycle 2-6 Day 1 (28 days cycle).10 minutes post-infusion on Cycle 1 Day 15 and Cycle 6 Day 22 (28 days cycle ) .10 minutes and 4 hours post-infusion on Cycle 1 Day 1 (28 days cycle).
Pharmacokinetics - T1/2
Time Frame: Within 60 minutes prior to infusion on Cycle 1 Day 1, Day 8, Day 15 and Cycle 2-6 Day 1 (28 days cycle).10 minutes post-infusion on Cycle 1 Day 15 and Cycle 6 Day 22 (28 days cycle ) .10 minutes and 4 hours post-infusion on Cycle 1 Day 1 (28 days cycle).
Terminal half-life (T1/2)
Within 60 minutes prior to infusion on Cycle 1 Day 1, Day 8, Day 15 and Cycle 2-6 Day 1 (28 days cycle).10 minutes post-infusion on Cycle 1 Day 15 and Cycle 6 Day 22 (28 days cycle ) .10 minutes and 4 hours post-infusion on Cycle 1 Day 1 (28 days cycle).
Response Rate
Time Frame: When the last subject enrolled completes approximately 12 months of treatment

Response determined per European LeukemiaNet response criteria:

CR = bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count > 1.0 x 10e9/L; platelet count > 100 x 10e9/L; and independence of red cell transfusions.

CRi = all CR criteria except for residual neutropenia (< 1.0 x 10e9/L) or thrombocytopenia (< 100 x 10e9/L)].

To evaluate clinical benefit defined as CR, CRi, morphologic leukemia-free state, and partial remission (PR).
When the last subject enrolled completes approximately 12 months of treatment
Overall Remission (OR):
Time Frame: When the last subject enrolled completes approximately 12 months of treatment
Response Criteria are according to the Modified IWG (International Working Group) Response Criteria in Myelodysplasia.CR: bone marrow evaluation shows less than or equal to (<=) 5% blasts; normal maturation of all cells lines (mCR), peripheral blood evaluation shows hemoglobin >= 11 gram per deciliter (g/dL), neutrophils >= 1000/mL, platelets >= 100,000/mL, 0% blasts; PR: Same as CR, except blasts decrease by >=50%, still greater than 5% in bone marrow. Hematologic improvement are measured in participants with pretreatment abnormal values: hemoglobin level less than 110 g/L (11 g/dL) or red blood count (RBC)-transfusion dependence, platelet count <100 x 10^9/L or platelet-transfusion dependence, absolute neutrophil count (ANC) less than 1.0 x 10^9/L.
When the last subject enrolled completes approximately 12 months of treatment

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Exploratory Endpoint
Time Frame: In cycle 1(each cycle is 28 days) and cycle 4, 6, 8, 10, and 12, at the end of treatment or early study withdrawal, and 30 days after the last dose.
Anti-drug Antibody (ADA)
In cycle 1(each cycle is 28 days) and cycle 4, 6, 8, 10, and 12, at the end of treatment or early study withdrawal, and 30 days after the last dose.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Collaborators

Institute of Hematology & Blood Diseases Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 5, 2022

Primary Completion (Anticipated)

February 5, 2024

Study Completion (Anticipated)

March 1, 2024

Study Registration Dates

First Submitted

October 17, 2021

First Submitted That Met QC Criteria

November 21, 2021

First Posted (Actual)

December 1, 2021

Study Record Updates

Last Update Posted (Actual)

May 24, 2023

Last Update Submitted That Met QC Criteria

May 22, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IMM01-02

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe